Moderate Aortic Stenosis and Ventricular Dysfunction: Should Valve Replacement Come Sooner?

Moderate Aortic Stenosis and Ventricular Dysfunction: Should Valve Replacement Come Sooner?Ventricular dysfunction and moderate aortic stenosis are more frequent with advancing age and often coexist. Afterload reduction is one of the main pillars of pharmacological treatment of heart failure, and aortic stenosis (even that of moderate severity) increases the afterload. Nowadays, aortic valve replacement is only formally indicated for symptomatic severe aortic stenosis.

 

This study seeks to determine the outcome of patients with concomitant moderate aortic stenosis and ventricular dysfunction. Echocardiographic and clinical data of 305 patients from 4 large university hospitals between 2010 and 2015 were retrospectively analyzed.

 

Moderate aortic stenosis was defined as aortic valve area between 1 and 1.5 cm2 and ventricular dysfunction was defined as left ventricular ejection fraction <50%. The primary endpoint was a composite of all-cause death, valve replacement, and heart failure hospitalization.

 

Most patients were symptomatic at the time of index echocardiogram (New York Heart Association [NYHA] functional class [FC] II: 42%; FC III: 28%; and FC IV: 4%) and 72% of them presented associated ischemic heart disease.

 

At 4-year follow-up, the primary composite endpoint occurred in 61% of patients.

The main predictors for the primary endpoint were male sex (p = 0.022), FC III or IV (p < 0.001), and peak aortic jet velocity (p < 0.001).

 

The rate of death at follow-up was 36%, and the composite of death or heart failure hospitalization was 48%. Additionally, 24% of patients underwent valve replacement.

 

Conclusion

Patients with concomitant moderate aortic stenosis and ventricular dysfunction are at high risk for clinical events. However, further studies are needed to determine if earlier valve replacement in these patients might improve clinical outcome.

 

Editorial

The combination of moderate aortic stenosis and ventricular dysfunction among the general population is probably underestimated and likely to become more frequent with advancing age. Some population studies have shown a prevalence of around 3% for this combination among people of over 75 years old.

 

So far, the evidence supporting a more aggressive approach as regards valve replacement is indirect and retrospective, but it does warrant an exploratory analysis of the indication of transcatheter aortic valve replacement (TAVR) for this population.

 

Original title: Prognostic Implications of Moderate Aortic Stenosis in Patients with Left Ventricular Systolic Dysfunction.

Reference: Lennart van Gils et al. J Am Coll Cardiol 2017; 69:2383–92.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe aortic stenosis across different risk groups. While previous...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...